Pramipexole; Placebo
Проводит Boehringer Ingelheim
Страница компанииLong-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00577460/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 32 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 391 чел. во всех странах исследования.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 4 · невключение: 19
Критерии включения
- Completion of the double-blind trial 248.525
- Male or female patient with advanced idiopathic Parkinson's disease (PD), with a Modified Hoehn and Yahr stage of 2 to 4 at on-time, and a concomitant treatment with standard or controlled release L-Dopa+, or a combination of L-Dopa+ and entacapone.
- Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. In particular the patient should be able to recognise the off-time and on-time periods during waking hours and the patient (or a family member or a guardian) should be able to record them accurately in the patient diary.
- Signed informed consent obtained before any study procedures are carried out (in accordance with International Conference of Harmonization - Good Clinical Practice (ICH-GCP) guidelines and local legislation).
Критерии невключения
- Patients prematurely withdrawn from the double-blind trial 248.525
- Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases
- Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study
- History of psychosis, except history of drug induced hallucinations
- History of deep brain stimulation
- Clinically significant ECG abnormalities at baseline
- Clinically significant hypotension and/or symptomatic orthostatic hypotension at baseline
- Malignant melanoma or history of previously treated malignant melanoma
- Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study
- Pregnancy or breast-feeding
- Sexually active female of childbearing potential not using a medically approved method of birth control
- Serum levels of aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase (SGOT)), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase) (SGPT)), alkaline phosphatase (AP) or bilirubin > 2 upper limit normal (ULN) at baseline
- Patients with a creatinine clearance < 50 mL/min at baseline
- Any medication with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit
- Any of the following drugs within 4 weeks prior to baseline visit: methylphenidate, cinnarizine, amphetamines
- Flunarizine within 3 months prior to baseline
- Known hypersensitivity to pramipexole or its excipients
- Drug abuse, according to investigators judgement, within 2 years prior to baseline
- Participation in investigational drug studies other than the trial 248.525, or use of other investigational drugs within one month or five times the half-life of the investigational drug (whichever is longer) prior to baseline
Источник: ClinicalTrials.gov, NCT00577460 · запись обновлена в реестре 16 мая 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 31
- Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 80 weeks
Цель исследования
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in patients who have previously completed a pramipexole double-blind study in advanced Parkinson's disease (PD) (248.525 trial).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00577460 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.